Trial · NCT02129075
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Immune T-cell Response to NY-ESO-1 | Arm I (CDX-301, CDX-1401, and Poly-ICLC) | 15 | Participants | ||
| Immune T-cell Response to NY-ESO-1 | Arm II (CDX-1401 and Poly-ICLC) | 10 | Participants | ||
| T Cell Responses to Other Ongoing and Nascent Antitumor Response Antigens Associated With Melanoma (e.g. PRAME, MAGE-A3, p53, and gp1000) as Well as Memory and Chronic Viral Responses (CMV, EBV) | Arm I (CDX-301, CDX-1401, and Poly-ICLC) | 7 | Participants | ||
| T Cell Responses to Other Ongoing and Nascent Antitumor Response Antigens Associated With Melanoma (e.g. PRAME, MAGE-A3, p53, and gp1000) as Well as Memory and Chronic Viral Responses (CMV, EBV) | Arm II (CDX-1401 and Poly-ICLC) | 7 | Participants | ||
| Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold) | Arm I (CDX-301, CDX-1401, and Poly-ICLC) | cDCs | 30.4 | Standard Deviation 16.98 | log 2 fold change |
| Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold) | Arm II (CDX-1401 and Poly-ICLC) | cDCs | 0.9 | Standard Deviation 0.26 | log 2 fold change |
| Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold) | Arm I (CDX-301, CDX-1401, and Poly-ICLC) | Monocytes | 6.1 | Standard Deviation 2.11 | log 2 fold change |
| Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold) | Arm II (CDX-1401 and Poly-ICLC) | Monocytes | 1.0 | Standard Deviation 0.18 | log 2 fold change |
| Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold) | Arm I (CDX-301, CDX-1401, and Poly-ICLC) | CD4 T cells | 1.2 | Standard Deviation 0.28 | log 2 fold change |
| Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold) | Arm II (CDX-1401 and Poly-ICLC) | CD4 T cells | 1.1 | Standard Deviation 0.27 | log 2 fold change |
| Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold) | Arm I (CDX-301, CDX-1401, and Poly-ICLC) | NK CD56br cells | 5.8 | Standard Deviation 2.84 | log 2 fold change |
| Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold) | Arm II (CDX-1401 and Poly-ICLC) | NK CD56br cells | 1.26 | Standard Deviation 0.32 | log 2 fold change |
| Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold) | Arm I (CDX-301, CDX-1401, and Poly-ICLC) | CD8 T cells | 1.3 | Standard Deviation 0.36 | log 2 fold change |
| Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold) | Arm II (CDX-1401 and Poly-ICLC) | CD8 T cells | 1.0 | Standard Deviation .26 | log 2 fold change |
| Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold) | Arm I (CDX-301, CDX-1401, and Poly-ICLC) | pDC | 16.5 | Standard Deviation 7.27 | log 2 fold change |
| Frequency and Phenotypic Character of PBMC Subsets Including DCs, Monocyte Populations, T Cells, and NK Cells - Highest Peak Fold Change Over Baseline (Log 2 Fold) | Arm II (CDX-1401 and Poly-ICLC) | pDC | 0.8 | Standard Deviation 0.24 | log 2 fold change |
| Tumor Recurrence | Arm I (CDX-301, CDX-1401, and Poly-ICLC) | 360.3 | Standard Deviation 191.1 | days | |
| Tumor Recurrence | Arm II (CDX-1401 and Poly-ICLC) | 389.2 | Standard Deviation 223.2 | days |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02129075/results